Myelodysplastic Syndromes (MDS) are conditions that can occur when the blood cells in the bone marrow become abnormal. It is considered as a type of cancer. Myelodysplastic syndromes affect hematopoiesis at the stem cell level, as indicated by cytogenetic abnormalities, molecular mutations, and morphologic and physiologic abnormalities in mutation and differentiation of one or more of the hematopoietic cell lines. The dysplastic cells in the bone marrow have problem in making new blood cells. Many of the blood cells formed by these bone marrow cells, and the body also destroys some abnormal blood cells, leaving the person without enough normal blood cells. Different cell types can be affected, although the most common finding in myelodysplastic syndrome is a shortage of red blood cells. Myelodysplastic syndromes rarely cause signs or symptoms in the early stages. In time, it might cause fatigue, shortness of breath, frequent infections, easy or unusual bruising or bleeding which occurs due to a low blood platelet.
The report provides Myelodysplastic Syndrome treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.
Major industry players profiled as part of the report are Sclnow Biotechnology Co. Ltd., Sumitomo Dainippon Pharma Co., Fujifilm Pharmaceuticals U.S.A., Inc., Johnson & Johnson Services, Inc., AstraZeneca, Celgene Corporation, F. Hoffmann-La Roche Ltd., Onconova Therapeutics Inc., Amgen Inc, Apogenix AG, GlaxoSmithKline plc, SymBio Pharmaceuticals, Kura Oncology, Inc., Opsona Therapeutics, CrystalGenomics Inc., Helsinn Healthcare SA., MEI Pharma Inc., Groupe Francophone des Myelodysplasies, Acceleron Pharma, Inc., Boehringer Ingelheim International GmbH, Karyopharm Therapeutics, Eli Lilly and Company, AbbVie Inc., Amphivena Therapeutics, Inc., MabVax Therapeutics Holdings, Inc., medac GmbH, Astex Pharmaceuticals, Stemline Therapeutics, Inc., Calithera Biosciences, Inc., Array BioPharma, Mirati Therapeutics, Qol-one, Syros Pharmaceuticals, Inc., Kyowa Kirin Pharmaceutical Development, Inc., Aileron Therapeutics, Medpacto, Inc., Pfizer Inc., BioMed Valley Discoveries Inc., BioLineRx., CTI BioPharma Corp., Sunesis Pharmaceuticals, Inc., Immune System Key (Isk) Ltd., Takeda Pharmaceutical Company Limited., BerGenBio ASA, Cell Medica, Forty Seven Inc., Imago BioSciences, CytoDyn Inc., OncoTherapy Science, Inc., Mateon Therapeutics, Inc., Bellicum Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited., Plexxikon, FibroGen, Inc., argenx US Inc., Kiadis Pharma, Aprea Therapeutics, Forma Therapeutics, Inc., Agios, Inc, Actinium Pharmaceuticals, Inc., Aeglea BioTherapeutics, BAYER AG, Altor BioScience, Rafael Pharmaceuticals, Inc., H3 Biomedicine Inc., Cellerant Therapeutics, Inc., and Boston Biomedical.
Scope:
By Company
By Phase
By Molecule Type
By Region
By Route of Administration